Results of the PEGASUS phase 3 randomized trial demonstrating superiority of the C3 inhibitor, pegcetacoplan, compared to eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH)

Roeth, A, Hillmen, P orcid.org/0000-0001-5617-4403, Szer, J et al. (16 more authors) (2020) Results of the PEGASUS phase 3 randomized trial demonstrating superiority of the C3 inhibitor, pegcetacoplan, compared to eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH). In: Conference of the German, Austrian and Swiss Societies for Hematology and Medical Oncology, 09-11 Oct 2020, Online.

Metadata

Authors/Creators:
  • Roeth, A
  • Hillmen, P ORCID logo https://orcid.org/0000-0001-5617-4403
  • Szer, J
  • Weitz, I
  • Hoechsmann, B
  • Panse, J
  • Schafhausen, P
  • Usuki, K
  • Griffin, M
  • Kiladjian, J-J
  • de Castro, C
  • Nishimori, H
  • Tan, L
  • Hamdani, M
  • Deschatelets, P
  • Francois, C
  • Grossi, F
  • Risitano, A
  • de Latour, PR
Dates:
  • Published: October 2020
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 26 Jan 2021 12:47
Last Modified: 26 Jan 2021 12:47
Status: Published
Identification Number: https://doi.org/10.1159/000510995
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)